Over the past decade, antisense technology has successfully established itself as an
entirely innovative platform for research and creation of new therapies. Significant advances in
the design of antisense oligonucleotides, as well as a deeper understanding of their
mechanisms of action, have led to their successful clinical application in many RNA-targeted
therapies. In addition, their potential for in vivo imaging by radiolabeling has been identified. In
this regard, a scientific publication in English was successfully written by a group of scientists
from the “Cyclotron physics” laboratory of INRNE-BAS and accepted for publication. In the
paper we are discussing the prospects for the use of antisense oligonucleotides in nuclear
medicine, as well as highlighting some of the advantages and disadvantages of labelling them
with radionuclides. The title of the paper is “Antisense oligonucleotides and radionuclides-
perspectives”, written by Dr. Katya B. Popova, Maria Mincheva, Dr. Maria Yavahchova, Dr.
Nikolay Goutev and Prof. Dr. Dimitar Tonev. The review is published in Journal of
ECOLOGICAL ENGINEERING AND ENVIRONMENT PROTECTION. For further information
you can click on the following link:
INRNE-BAS